{"product_id":"global-cancer-minimal-residual-disease-testing-market-growth-2023-2029","title":"Global Cancer Minimal Residual Disease Testing Market Growth 2023-2029","description":"\u003cp\u003eGlobal Cancer Minimal Residual Disease Testing Market Growth 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eMinimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.\u003cbr\u003e\nLPI (LP Information)' newest research report, the “Cancer Minimal Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Cancer Minimal Residual Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Minimal Residual Disease Testing sales for 2023 through 2029. With Cancer Minimal Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Minimal Residual Disease Testing industry.\u003cbr\u003e\nThis Insight Report provides a comprehensive analysis of the global Cancer Minimal Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Minimal Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Minimal Residual Disease Testing market.\u003cbr\u003e\nThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Minimal Residual Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Minimal Residual Disease Testing.\u003cbr\u003e\nThe global Cancer Minimal Residual Disease Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003cbr\u003e\nUnited States market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003cbr\u003e\nChina market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003cbr\u003e\nEurope market for Cancer Minimal Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003cbr\u003e\nGlobal key Cancer Minimal Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003cbr\u003e\nThis report presents a comprehensive overview, market shares, and growth opportunities of Cancer Minimal Residual Disease Testing market by product type, application, key manufacturers and key regions and countries.\u003cbr\u003e\nMarket Segmentation:\u003cbr\u003e\nSegmentation by type\u003cbr\u003e\n Flow Cytometry\u003cbr\u003e\n Polymerase Chain Reaction (PCR)\u003cbr\u003e\n Next-Generation Sequencing (NGS)\u003cbr\u003e\n Other\u003cbr\u003e\nSegmentation by application\u003cbr\u003e\n Hematological Malignancies\u003cbr\u003e\n Leukemia\u003cbr\u003e\n Lymphoma\u003cbr\u003e\n Solid Tumors\u003cbr\u003e\n Other\u003cbr\u003e\nThis report also splits the market by region:\u003cbr\u003e\n Americas\u003cbr\u003e\n United States\u003cbr\u003e\n Canada\u003cbr\u003e\n Mexico\u003cbr\u003e\n Brazil\u003cbr\u003e\n APAC\u003cbr\u003e\n China\u003cbr\u003e\n Japan\u003cbr\u003e\n Korea\u003cbr\u003e\n Southeast Asia\u003cbr\u003e\n India\u003cbr\u003e\n Australia\u003cbr\u003e\n Europe\u003cbr\u003e\n Germany\u003cbr\u003e\n France\u003cbr\u003e\n UK\u003cbr\u003e\n Italy\u003cbr\u003e\n Russia\u003cbr\u003e\n Middle East \u0026amp; Africa\u003cbr\u003e\n Egypt\u003cbr\u003e\n South Africa\u003cbr\u003e\n Israel\u003cbr\u003e\n Turkey\u003cbr\u003e\n GCC Countries\u003cbr\u003e\nThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\n Adaptive Biotechnologies Corporation\u003cbr\u003e\n ArcherDX, Inc. (Invitae Corporation)\u003cbr\u003e\n Asuragen\u003cbr\u003e\n Arup Laboratories\u003cbr\u003e\n Bio-Rad Laboratories\u003cbr\u003e\n Cergentis B.V.\u003cbr\u003e\n F. Hoffmann- La Roche Ltd\u003cbr\u003e\n Guardant Health\u003cbr\u003e\n ICON plc\u003cbr\u003e\n Invivoscribe\u003cbr\u003e\n Laboratory Corporation of America Holdings\u003cbr\u003e\n Mission Bio\u003cbr\u003e\n Natera, Inc.\u003cbr\u003e\n NeoGenomics Laboratories\u003cbr\u003e\n Opko Health\u003cbr\u003e\n Quest Diagnostics Incorporated\u003cbr\u003e\n Sysmex Corporation\u003cbr\u003e\n Genetron Health\u003cbr\u003e\nKey Questions Addressed in this Report\u003cbr\u003e\nWhat is the 10-year outlook for the global Cancer Minimal Residual Disease Testing market?\u003cbr\u003e\nWhat factors are driving Cancer Minimal Residual Disease Testing market growth, globally and by region?\u003cbr\u003e\nWhich technologies are poised for the fastest growth by market and region?\u003cbr\u003e\nHow do Cancer Minimal Residual Disease Testing market opportunities vary by end market size?\u003cbr\u003e\nHow does Cancer Minimal Residual Disease Testing break out type, application?\u003cbr\u003e\nWhat are the influences of COVID-19 and Russia-Ukraine war?\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 113 Pages \/ MCW16234363","offer_id":47650938388786,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-cancer-minimal-residual-disease-testing-market-growth-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}